Evolus Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

David Moatazedi

İcra Kurulu Başkanı

US$11.2m

Toplam tazminat

CEO maaş yüzdesi	6.1%
CEO görev süresi	6.5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	6.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

David Moatazedi'un ücretlendirmesi Evolus'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$55m
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$60m
Dec 31 2023	US$11m	US$688k	-US$62m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$72m
Dec 31 2022	US$4m	US$597k	-US$74m
Sep 30 2022	n/a	n/a	-US$79m
Jun 30 2022	n/a	n/a	-US$79m
Mar 31 2022	n/a	n/a	-US$71m
Dec 31 2021	US$4m	US$572k	-US$47m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$131m
Mar 31 2021	n/a	n/a	-US$137m
Dec 31 2020	US$3m	US$527k	-US$163m
Sep 30 2020	n/a	n/a	-US$67m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$99m
Dec 31 2019	US$2m	US$550k	-US$90m
Sep 30 2019	n/a	n/a	-US$88m
Jun 30 2019	n/a	n/a	-US$73m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$6m	US$362k	-US$47m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 11.24M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.45M ).

Tazminat ve Kazançlar: David şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

David Moatazedi (46 yo)

6.5yrs

Görev süresi

US$11,240,447

Tazminat

Mr. David Moatazedi is Independent Director at Biomerica Inc. from December 07, 2022. He has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Mo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Moatazedi	President	6.5yrs	US$11.24m	Veri yok
Sandra Beaver	Chief Financial Officer	2.2yrs	US$2.46m	0.052% $ 415.4k
Rui Avelar	Chief Medical Officer and Head of Research & Development	10.8yrs	US$2.93m	0.31% $ 2.5m
Nareg Sagherian	Head of Global Investor Relations & Corporate Communications	less than a year	Veri yok	Veri yok
Jeffrey Plumer	General Counsel	no data	Veri yok	Veri yok
Kurt Knab	Vice President of Sales	6.1yrs	Veri yok	Veri yok
Tomoko Yamagishi-Dressler	Chief Marketing Officer	1.3yrs	Veri yok	0.016% $ 129.3k
Jessica Novak	Senior Vice President of Human Resources	3yrs	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: 0K16 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Moatazedi	President	6.5yrs	US$11.24m	Veri yok
David Gill	Independent Director	6.8yrs	US$256.03k	0.043% $ 348.4k
Simone Blank	Director	6.8yrs	US$235.03k	0.86% $ 6.9m
Albert White	Independent Director	less than a year	Veri yok	Veri yok
Vikram Malik	Chairman of the Board	6.8yrs	US$271.03k	0.37% $ 3.0m
Karah Parschauer	Independent Director	5.3yrs	US$249.03k	0.049% $ 395.8k
Brady Stewart	Independent Director	2.8yrs	US$222.03k	0.071% $ 567.6k

6.5yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0K16 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.5 yıldır).

Evolus Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee

Chairman of the Board recently sold US$97k worth of stock

President recently sold US$204k worth of stock

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

Recent updates

Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.30 loss in 3Q 2023)

Evolus, Inc. Provides Earnings Guidance for the Year 2024

Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus, Inc. to Report Q3, 2024 Results on Nov 06, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.32 loss in 2Q 2023)

Evolus, Inc. Raises Financial Guidance for the Full Year of 2024

Evolus, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Chairman of the Board recently sold US$97k worth of stock

Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

President recently sold US$204k worth of stock

Forecast breakeven date moved forward to 2025

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 1Q 2023)

Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.08 loss per share (vs US$1.33 loss in FY 2022)

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold US$822k worth of stock

New minor risk - Insider selling

New major risk - Financial position

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Insufficient new directors

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold US$152k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.42 loss in 2Q 2022)

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

First quarter 2023 earnings released: US$0.26 loss per share (vs US$0.31 loss in 1Q 2022)

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Insufficient new directors

Full year 2022 earnings released: US$1.33 loss per share (vs US$0.94 loss in FY 2021)

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Insufficient new directors

Forecast to breakeven in 2025

Insufficient new directors

Insufficient new directors

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insufficient new directors

Independent Director recently bought US$91k worth of stock

Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.30 loss in 2Q 2021)

Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022

Insufficient new directors

Evolus, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Evolus, Inc. Completes Patient Enrollment in Phase II Clinical Study Evaluating Extra-Strength Dose of Jeuveau

Evolus, Inc. Announces Dermatologic Surgery Published A New Post Hoc Analysis of Its Phase III Studies Comparing Millennial Patients to Non-Millennials

Independent Director recently sold US$138k worth of stock

Evolus, Inc. Revises Earnings Guidance for the Year 2022